Ranbaxy acquires rights for Ochoa Labs’ skincare products
22 May 2009
Ranbaxy Laboratories Ltd said late on Thursday that it has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Ltd for its entire range of dermatological and lifestyle products.
However, it did not provide any financial details in its filing to the Bombay Stock Exchange.
Ranbaxy already has a presence in the dermatology market including steroids with products such as Zole-F, Suncros, Efflora, Fucidin and Teczine, it said in its statement. In India, the market in the dermatology segment is worth Rs1,950 crore a year, and it is growing rapidly at 11 per cent, according to the company.
The acquired brands command considerable equity with doctors and are market leaders in their respective categories, the Mohali, Punjab-based Ranbaxy said in its statement.
The products enjoy high margins because of their novelty and brand appeal, and will be initially marketed in India. They complement Ranbaxy's existing derma portfolio, it added.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
